People in the UK who are prescribed medical cannabis through a private clinic can now request flower from the global cannabis brand Cookies, according to a press release seen by leafie.
The first strain available, Hawaiian Rain, is a high-potency flower containing 31% THC. Priced at £11 a gram, it is the expensive flower available on prescription at the time of publication. Patients prescribed medical cannabis through private clinics and partnering pharmacies can request the product, which is described as meeting “the highest pharmaceutical-grade standards” from today, Monday, 14 April.
Cookies genetics have been made available through a partnership between SOMAI Group and Mamedica, a UK-based digital healthcare platform that offers both clinic and prescribing services to patients.
“This partnership with Cookies signals a new era for UK medical cannabis patients,” said Jon Robson, CEO and founder of Mamedica.
“By combining Mamedica’s clinical expertise with Cookies’ world-class genetics and brand heritage, we’re delivering premium cannabis products backed by science, safety, and patient-centred care.”
The flower has been supplied under an exclusive license deal between the US brand and SOMAÍ Group, a Portugal-based cannabis cultivation company, as reported by leafie in 2024. It is expected that further strains and extracts will be available to patients in the UK imminently.
“We’re excited to partner with Mamedica to bring Cookies to the UK medical cannabis space,” said Berner, Founder and CEO of Cookies. “Our goal has always been to make our genetics accessible to patients globally, and the UK is a key part of that mission.”
According to the press release, there are now an estimated 80,000 people actively receiving cannabis-based prescription medicines in the UK. By partnering with globally recognised brands such as Cookies, Mamedica says it is “not only expanding patient choice, but also evolving the conversation around symptomatic relief in the UK, ensuring more people can benefit from safe, high-quality cannabis-based treatments.”
